Tempus is a technology company focused on collecting and analyzing large volumes of molecular and clinical data.
Tempus is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful.
Tempus was founded in 2015 by Eric Lefkofsky & Brad Keywell and is based in Chicago, Illinois.
Tempus offers bioinformatics system to collect, cleanse, analyze, and apply data solutions to healthcare. The company enables physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform.
Tempus's genomic tests analyze DNA, RNA, and proteomic data to understand a patient's tumor at the molecular level so it can identify treatment options tailored to each and every patient.
Tempus ingest and organize clinical notes, lab reports, pathology images, and radiology scans to capture phenotypic, therapeutic, and outcomes data to understand the clinical context for each patient case.
Tempus's platform analyzes thousands of clinical and molecular data points, connecting physicians with up-to-date treatment options and relevant insights for patients based on their unique molecular profile and our advanced analytics and machine-learning algorithms.
Tempus is backed by investors including New Enterprise Associates, Baillie Gifford, Revolution, and T. Rowe Price, Novo Holdings and others. The company raised $100M Series G round on Mar 16, 2020. The latest round comes less than a year after Tempus raised $200M Series F on May 30, 2019. This new round brings Tempus' total funding to $620M to date
Tempus achieved a staggering $5B from the Series G on Mar 16, 2020. The company was previously valued at $3.1B from its Series F post money on May 30, 2019. Tempus has made three investments totalling over $100M, to date.